DOR BioPharma.

DOR BioPharma, announced that its program for the development of DOR201 has received for the prevention of acute radiation sickness enteritis ‘Fast Track’by the U.S. Food and Drug Administration . – ‘There are no FDA approved therapies to prevent acuteContinue reading… DOR BioPharma.